Loading cancer entity…
Loading cancer entity…
Clinical trials
238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04684368 | A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | recruiting | Phase 2 | 160 | Children's Oncology GroupNETWORK | 4 | Sep 23, 2026 | clinicaltrials |
| NCT02792582 | A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection | active not recruiting | Phase 2 | 160 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2026 |
| clinicaltrials |
| NCT06368817 | A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | recruiting | Phase 2 | 240 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT01419067 | A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection | active not recruiting | Phase 2 | 112 | St. Jude Children's Research HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05005715 | Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery | completed | Phase 2 | 64 | Seoul National University HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03224767 | Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | active not recruiting | Phase 2 | 24 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04042753 | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05233397 | ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 30 | Nationwide Children's HospitalOTHER | 3 | Apr 23, 2026 | clinicaltrials |
| NCT05465174 | Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults(PNOC029) | recruiting | Phase 2 | 57 | Sabine Mueller, MD, PhDOTHER | 2 | Apr 23, 2026 | clinicaltrials |
| NCT07539792 | Efficacy and Safety Evaluation of Absorbable and Moldable Skull Base Support Plates in Extended Endoscopic Endonasal Transsphenoidal Surgery: A Prospective, Randomized, Controlled Study(EEEA-AMSBP) | recruiting | Phase 2 | 126 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 38 | Nationwide Children's HospitalOTHER | 3 | Apr 8, 2026 | clinicaltrials |
| NCT06970145 | Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma | recruiting | Phase 1 / Phase 2 | 57 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06299891 | Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity | recruiting | Phase 2 | 24 | Seattle Children's HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05525273 | Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma(Swecranio) | recruiting | Phase 2 | 25 | Eva Marie Erfurth, MD, PhDOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02842723 | Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) | completed | Phase 2 | 33 | Institut CurieOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01689727 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors | completed | Phase 2 | 40 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02849743 | Intranasal Oxytocin in Hypothalamic Obesity | completed | Phase 2 | 18 | Shana McCormack, MDOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT03930771 | Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas(TMZ-Cap) | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04863339 | Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery | withdrawn | Phase 2 | 0 | University of North Carolina, Chapel HillOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT02749227 | Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors(PASSILCORT) | terminated | Phase 2 | 4 | Columbia UniversityOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04335357 | TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas | unknown | Phase 2 | 150 | Tiburio TherapeuticsINDUSTRY | 0 | Apr 6, 2020 | clinicaltrials |
| NCT04244708 | The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas | unknown | Phase 2 / Phase 3 | 150 | Peking Union Medical College HospitalOTHER | 0 | Jan 28, 2020 | clinicaltrials |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | completed | Phase 2 | 9 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01283542 | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.(Passion I) | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT00929669 | Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas(LAR) | terminated | Phase 2 | 2 | University of PennsylvaniaOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01484873 | Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor | completed | Phase 2 | 10 | Vanderbilt University Medical CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00958841 | Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | terminated | Phase 2 | 118 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 26, 2016 | clinicaltrials |
| NCT02063295 | An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury | completed | Phase 2 | 14 | Zafgen, Inc.INDUSTRY | 2 | Jul 18, 2016 | clinicaltrials |
| NCT01203618 | Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas | withdrawn | Phase 2 | 0 | MorphotekINDUSTRY | 1 | Nov 4, 2013 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT00697814 | Clomiphene in Males With Prolactinomas and Persistent Hypogonadism | completed | Phase 2 | 15 | Federal University of São PauloOTHER | 1 | Jun 16, 2008 | clinicaltrials |
| NCT00001860 | Sandostatin LAR Depot vs. Surgery for Treating Acromegaly | completed | Phase 2 | 5 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials